Skip to main content
2024 Guide to Patient Support Services

Ipsen Biopharmaceuticals

2024 PSS Guide

IPSEN CARES: Coverage, Access, Reimbursement & Education Support

Ipsen Biopharmaceuticals provides several patient support services through its IPSEN CARES (Coverage, Access, Reimbursement & Education Support) program to patients who are prescribed Onivyde or Somatuline Depot (Table).

IPSEN CARES Support Services

Through its various services, Ipsen facilitates access to Onivyde and Somatuline Depot for patients who are insured, underinsured, or uninsured by assisting with insurance verification, determination of out-of-pocket costs, prior authorization, and claims appeals.

To access these services, patients must be enrolled in IPSEN CARES. The patient and the healthcare provider can download the IPSEN CARES Enrollment Form and complete it at the office. The form can be submitted electronically or by printing and faxing the completed form to IPSEN CARES at 888-525-2416. For answers to questions about the program, call IPSEN CARES at 866-435-5677.

Onivyde Copay Assistance Program

Eligible, commercially insured patients being treated with Onivyde may pay as little as $0 per prescription and may receive up to $20,000 in savings during the program year. The program resets every January 1, and IPSEN CARES will confirm with the patient annually that the criteria for the program are still being met.

“Cash-pay” patients, defined for purposes of this program as patients without insurance coverage or those who have commercial insurance that does not cover Onivyde, are eligible to participate.

Patients are not eligible for the Onivyde Copay Assistance Program if they are enrolled in any federal- or state-­funded program including, but not limited to, Medicare Part B, Medicare Part D, Medicaid, Medigap, Veterans Administration, Department of Defense, or TRICARE.

Other terms and conditions apply.

Somatuline Depot Copay Assistance Program

Somatuline Depot is covered under both pharmacy and medical benefits. You and your patient can decide which method is best suited to each patient. Both programs are available to all eligible patients, but a patient may participate in only 1 program at a time.

To be eligible for these programs, patients must be receiving treatment with Somatuline Depot; have com­mercial insurance that covers Somatuline Depot and its associated cost, or be uninsured and pay their entire cost out of pocket; and not be enrolled in a federal- or state-subsidized healthcare or pharmaceutical assistance program, including Medicare, Medicare Part D, Medicaid, or TRICARE.

Ipsen Patient Assistance Program

Uninsured patients may be eligible to receive free medication through the Patient Assistance Program. Patients must be US residents who are experiencing financial hardship; have a prescription for an on-label use of Onivyde or Somatuline Depot, as supported by information provided in the program application; and have no insurance coverage. Patients can download the Patient Financial Support Application form and apply for the program through IPSEN CARES.

Specific terms and conditions, including income criteria, may apply.

Nonprofit Organization Support

The IPSEN CARES program is staffed by patient access specialists who can assist in supplying referrals to independent nonprofit organizations for patients in need, including those who have government-provided insurance.

TABLE Ipsen Oncology Drugs

Patient support programs

Onivyde (irinotecan liposome injection)
Treatment of metastatic adenocarcinoma of the pancreas that progressed after gemcitabine-based therapy, in combination with fluorouracil and leucovorin
Patient support programs

Somatuline Depot (lanreotide) injection
Treatment of carcinoid syndrome; unresectable, well-differentiated or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors
Patient support programs

Tazverik (tazemetostat) tablets
Treatment of patients aged ≥16 years with metastatic or locally advanced epithelioid sarcoma who are not eligible for complete resection; treatment of adults with relapsed or refractory follicular lymphoma (FL) and EZH2 mutation, as detected by an FDA-approved test, who have received ≥2 prior systemic therapies; treatment of adults with relapsed or refractory FL who have no satisfactory alternative treatment options
Patient support programs